{"organizations": [], "uuid": "76cfed4f30a391a5e460f78b48e561f3d39571d8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-announces-tafamidis-phase-3/brief-pfizer-announces-tafamidis-phase-3-attr-act-study-met-its-primary-endpoint-idUSFWN1RB0Y8", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-29T19:49:00.000+03:00", "replies_count": 0, "uuid": "76cfed4f30a391a5e460f78b48e561f3d39571d8"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-announces-tafamidis-phase-3/brief-pfizer-announces-tafamidis-phase-3-attr-act-study-met-its-primary-endpoint-idUSFWN1RB0Y8", "ord_in_thread": 0, "title": "BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "pfizer inc", "sentiment": "none"}, {"name": "study met its primary endpoint reuters staff", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29, 2018 / 4:51 PM / Updated 11 minutes ago BRIEF-Pfizer Announces Tafamidis Phase 3 ATTR-ACT Study Met Its Primary Endpoint Reuters Staff 1 Min Read \n  Pfizer Inc: \n* PFIZER ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTR-ACT STUDY OF TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY \n* PFIZER INC - STUDY MET ITS PRIMARY ENDPOINT \n* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED \n* PFIZER INC - PRELIMINARY SAFETY DATA SHOWED THAT TAFAMIDIS WAS GENERALLY WELL TOLERATED IN POPULATION AND NO NEW SAFETY SIGNALS WERE IDENTIFIED Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-29T19:49:00.000+03:00", "crawled": "2018-03-29T20:04:26.005+03:00", "highlightTitle": ""}